Clinical Trials
14 trialsNCT06325683 2026-05-26
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Suspended
NCT04003649 2026-05-14
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04145115 2026-05-04
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04817254 2026-04-17
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
NCT04606316 2026-02-17
Surgical Nivolumab And Ipilimumab For Recurrent GBM
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03743662 2026-01-07
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07031765 2025-12-18
Peds CHAMP1ON
University of Florida
Phase 1 Active not recruiting
NCT03718767 2025-11-24
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT03233152 2025-11-21
GlitIpNi
Universitair Ziekenhuis Brussel
Phase 1/2 Active not recruiting
NCT02327078 2025-08-14
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
Phase 1/2 Completed
NCT03636477 2025-08-12
A Study of Ad-RTS-hIL-12 With Veledimex in Combination With Nivolumab in Subjects With Glioblastoma; a Substudy to ATI001-102
Alaunos Therapeutics
Phase 1 Completed
NCT04047706 2025-06-29
Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
Phase 1 Active not recruiting
NCT06896110 2025-06-26
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
University of Iowa
Phase 1 Enrolling by invitation